ADMA Biologics(ADMA) ZACKS·2025-02-19 23:51Company Performance - Adma Biologics (ADMA) closed at 0.15, representing a 275% increase from the same quarter last year [2] - Revenue is estimated to be $112.2 million, reflecting a 51.83% increase from the prior-year quarter [2] Analyst Forecasts - Recent revisions to analyst forecasts for Adma Biologics are important as they indicate evolving short-term business trends, with positive revisions suggesting optimism about the company's outlook [3] - The Zacks Rank system, which incorporates estimate changes, aims to provide actionable ratings based on these revisions [4] Zacks Rank and Valuation - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate moving 2.24% higher over the past month [5] - The company has a Forward P/E ratio of 23.61, which is a premium compared to the industry average Forward P/E of 22.58 [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Adma Biologics, holds a Zacks Industry Rank of 68, placing it in the top 28% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, indicating that top-rated industries outperform lower-rated ones by a factor of 2 to 1 [7]